Novartis has teamed with the French drug maker Servier to develop and commercialize novel drug candidates targeting apoptosis in oncology.
Novartis has teamed with the French drug maker Servier to develop and commercialize novel drug candidates targeting apoptosis in oncology.
The collaboration covers BCL-2 selective inhibitor candidates - developed by Servier and Vernalis - currently entering clinical development. Proteins of the BCL-2 family are crucial regulators of apoptosis (programmed cell death).
“These new compounds further extends Servier’s portfolio beyond kinase inhibitors, HDAC inhibitors and immunitherapeutic products,” said Dr Jean-Pierre Abastado of Servier’s Center of Therapeutic Innovation in Oncology.
